Serum Endocan Levels Associated with Hypertension and Loss of Renal Function in Pediatric Patients after Two Years from Renal Transplant

Table 2

Characteristics of the study population after transplantation.

Characteristic
Age (years)	14.5 (3.3); (13.6–15.4)
Height (cm)	149.5 (16.6); (144.9–154.1)
Weight (Kg)	45.5 (16.2); (41.0–49.6)
BMI (Kg/m^2)	19.9 (4.5); (18.6–21.2)
SBP (mmHg)	125 (13.5); (121–128)
DBP (mmHg)	83 (12.4); (80–87)
PP (mmHg)	42 (13.2); (38–45)
sCr (mg/dL)	1.01 (0.28); (0.93–1.09)
eGFR (mL/min/1.73 m^2)	64.3 (17.6); (59.4–69.2)
Endocan (ng/mL)	12.5 (4.2); (11.3–13.6)
Immunosuppressive therapy
TAC + MMF + AZA	5 (8)
AZA + MMF	12 (18)
PRED + AZA + CSA	4 (6)
PRED + TAC + AZA	32 (53)
PRED + TAC	9 (15)
Antihypertensive therapy
ACE-I + CCBs	4 (14)
ACE-I + ARBs	5 (18)
ARBs + CCBs + β-blockers	4 (14)
Diuretics + CCBs + β-blockers	8 (29)
CCBs	7 (25)

Data are reported as number with percent in parentheses or mean with standard deviation and 95% confidence interval in parentheses. BMI: body mass index; SBP: systolic blood pressure; DBP: diastolic blood pressure; PP: pulse pressure; sCr: serum creatinine; eGFR: glomerular filtration rate estimated by creatinine; TAC: tacrolimus; MMF: mycophenolate mofetil; AZA: azathioprine; CSA: cyclosporine A; PRED: prednisone; ACE-I: ACE inhibitors; CCBs: calcium channel blockers; ARBs: angiotensin receptor blockers.